Artivion

Artivion(AORT)

KENNESAW, GA
Biotechnology
WebsiteLinkedInCareers Page

Focus: Tissues, surgical adhesives, additional devices

Artivion is a life sciences company focused on Tissues, surgical adhesives, additional devices.

Cardiovascular
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT03669042Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery
N/A
PerClot Polysaccharide Hemostatic System
Blood Loss, Surgical
N/A
Clinical Trials (1)
NCT02359994Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System
N/A
Chord-X system implant
Mitral Regurgitation (MR)
N/A
Clinical Trials (1)
NCT07413926Mitral Valve Repair With the Chord-X System: A Long Term Evaluation
N/A
Arcevo™ LSA Hybrid Stent Graft System
Aortic Arch Aneurysm
N/A
Clinical Trials (1)
NCT07089576Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
N/A
Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revasc
Critical Limb Ischemia
N/A
Clinical Trials (1)
NCT01799811Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization
N/A
N/A
Clinical Trials (1)
NCT03035643DARTS I Feasibility Study
N/A
N/A
Clinical Trials (1)
NCT05174767PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
N/A
N/A
Clinical Trials (1)
NCT05314868Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery
N/A
N/A
Clinical Trials (1)
NCT03397251DARTS I: Feasibility, Safety, and Performance Trial
N/A
Phase 3
Clinical Trials (1)
NCT04142658PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1984
Portfolio: 10 clinical trials
SEC Filings: 2 available

Financials (FY2025)

Revenue
$354M13%
R&D Spend
$29M(8%)26%
Net Income
-$31M
Cash
$53M
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles